Eurofins Scientific SE

Last price update: 27 Feb 24 18:35 GMT

Price:
EUR54.74
Open:
EUR55.58
Previous close:
EUR58.64
Day's range:
EUR51.32 - EUR55.68
Year's range:
EUR44.83 - EUR68.42
Net Income per Share:
2.28
Price-to-Earnings ratio:
24.01
52-week Price Range:
EUR56.84
Volume:
EUR1,355,638.00
Average volume:
EUR306,120.00

Company profile for Eurofins Scientific SE

Eurofins Scientific SE logo

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.

Stock exchanges:
EURONEXT
Sector:
Healthcare
Industries:
Diagnostics & Research
Ticker:
ERF.PA
ISIN:
FR0000038259
Website:
https://www.eurofins.com
Phone:
352 26 18 53 20
Origin:
Luxembourg
Employees:
61,000

Eurofins Scientific SE Press Releases

Eurofins acquires sundream group in taiwan

Eurofins becomes the market leader in environment testing in taiwan with the acquisition of the sundream group. transaction should be immediately margin accretive for eurofins after closing. sundream environment testing employs over 350 staff. transaction should be immediately margin accretive for eurofins after closing..

Eurofins technologies launches reagents for automated extraction of genomic sars cov 2 rna from CLI NIC al swab samples

Eurofins technologies launches reagents for automated extraction of genomic sars cov 2 rna from CLI NIC al swab samples. gsd novaprime rna extraction ae1 and ae2 kits are validated for use with kingfisher flex and mgi mgisp 960 automation platform.

Eurofins scientific acquires commissum

Eurofins digital testing expands cyber security portfolio with acquisition of commissum. terms were not disclosed. acquisition will help eurofin to strengthen position in european marketplace with growth in uk and in north american and apac marketplaces.

Eurofins technologies elisa assay is granted aoac research institute performance tested methods status

Eurofins technologies announces aoac performance tested methodssm status for sensispec ingezim gluten r5 kit. elisa assay for detection of gluten, sensispec ingezim gluten r5, has been granted aoac research institute performance tested methods( sm) status for use with gluten free bread, oat flour and stainless steel surfaces.

Eurofins scientific raises 535 million euros following a successful equity issuance

Eurofins raises eur 535 m following a successful equity issuance. books were multiple times oversubscribed and eurofins' management DEC ID ed to increase offer size from 900,000 to 1,000,000 new shares. settlement delivery and admission of new shares on euronext paris ( on the same line as eurofins’ existing shares with isin code fr0000038259) should occur on 22 may 2020.

Eurofins to issue 900,000 new shares via accelerated book building offering

Eurofins announces the issuance of c. 900,000 new shares via an accelerated book building offering to institutional investors in order to support its rapid build up of covid 19 testing capacities. the new ordinary shares would represent c. 5% of the existing issued share capital. purpose of placement is to enable eurofins to fund investments and net working capital needs. transaction is led by berenberg and credit suisse as joint global coordinators and joint bookrunners. is also preparing the launch of several additional covid 19 testing products for which production capacity has to be set up in europe and north america. the settlement delivery and the admission of the new shares on euronext paris should occur on 22 may 2020.